Osteoporosis and multiple sclerosis: Risk factors, pathophysiology, and therapeutic interventions

CNS Drugs

Volumn 28, Issue 8, 2014, Pages 731-742

  Gupta, Sahil ^a   Ahsan, Irfan ^a   Mahfooz, Naeem ^a   Abdelhamid, Noureldin ^a   Ramanathan, Murali ^a,b   Weinstock Guttman, Bianca ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UBMD Neurology Jacobs MS Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOMODULATING AGENT;

BONE REMODELING; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CORTICOSTEROID THERAPY; HEALTH STATUS; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSICAL INACTIVITY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; ANIMAL;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RISK FACTORS;

EID: 84904995014     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0173-3     Document Type: Review

References (101)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
2. Sa MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr. 2012;70(9):733-40.
3. Weinstock-Guttman B, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10(2):170-5.
4. Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler. 2010;16(9):1031-43.
5. Zorzon M, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12(7):550-6.
6. Marrie RA, et al. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009;73(17):1394-8.
7. Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci. 2009;287(1-2):1-6.
8. Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int. 2011;22(12):2935-49.
9. Josyula S, et al. The nervous system's potential role in multiple sclerosis associated bone loss. J Neurol Sci. 2012;319(1-2):8-14.
10. Ye S, Wu R, Wu J. Multiple sclerosis and fracture. Int J Neurosci. 2013;123(9):609-16.
11. Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012;18(4 Suppl B):S1-15 (discussion S13).
12. Cosman F, et al. Fracture history and bone loss in patients with MS. Neurology. 1998;51(4):1161-5.
13. Nieves J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44(9):1687-92.
14. Ozgocmen S, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23(4):309-13.
15. Achiron A, et al. Bone strength in multiple sclerosis: cortical midtibial speed-of-sound assessment. Mult Scler. 2004;10(5):488-93.
16. Moen SM, et al. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology. 2011;77(2):151-7.
17. Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am. 1998;27(2):255-65.
18. Sipos W, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr. 2009;159(9-10):230-4.
19. Luis Neyro J, Jesus Cancelo M, Palacios S. Inhibition of RANK-L in the pathophysiology of osteoporosis. Clinical evidences of its use. Ginecol Obstet Mex. 2013;81(3):146-57.
20. Negishi-Koga T, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473-80.
21. Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255(Suppl 6):2-6.
22. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305-11.
23. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134-9.
24. Altintas A, et al. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci. 2009;276(1-2):41-4.
25. Vogt MH, et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010;16(4):443-9.
26. Slavov GS, et al. Vitamin D immunomodulatory potential in multiple sclerosis. Folia Med (Plovdiv). 2013;55(2):5-9.
27. Munger KL, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60-5.
28. George PM, et al. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44-53.
29. Abraham AK, et al. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 2009;77(12):1757-62.
30. Moen SM, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One. 2012;7(9):e45703.
31. Thomas T, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140(4):1630-8.
32. Gordeladze JO, et al. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825-36.
33. Ducy P, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197-207.
34. Elefteriou F, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA. 2004;101(9):3258-63.
35. Ruhl CE, et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am J Clin Nutr. 2007;85(4):1121-6.
36. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002;60(10 Pt 2):S1-14 (discussion S68-84, 85-7).
37. Glauber HS, et al. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab. 1995;80(4):1118-23.
38. Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr. 1996;63(3 Suppl):433S-6S.
39. Carlton ED, Demas GE, French SS. Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors. Horm Behav. 2012;62(3):272-9.
40. Yadav VK, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976-89.
41. Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des. 2003;9(10):811-8.
42. De Rosa V, et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest. 2006;116(2):447-55.
43. Matarese G, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol. 2001;166(10):5909-16.
44. Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fund Clin Pharmacol. 2009;23(2):149-57.
45. Sato S, et al. Central control of bone remodeling by neuromedin U. Nat Med. 2007;13(10):1234-40.
46. Shi YC, Baldock PA. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone. 2012;50(2):430-6.
47. Khor EC, Baldock P. The NPY system and its neural and neuroendocrine regulation of bone. Curr Osteoporos Rep. 2012;10(2):160-8.
48. Inose H, et al. Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res. 2011;26(9):2002-11.
49. Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med. 2011;62:323-31.
50. Yuan XQ, et al. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201-8.
51. Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514-20.
52. Shi Y, et al. Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab. 2010;11(3):231-8.
53. Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001;158(2):257-67.
54. Didilescu AC, et al. The role of smoking in changing essential parameters in body homeostasis. Pneumologia. 2009;58(2):89-94.
55. Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol. 1992;49(12):1243-7.
56. Zivadinov R, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73(7):504-10.
57. Manouchehrinia A, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136(Pt 7):2298-304.
58. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154(1):69-74.
59. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53(12):920-6.
60. Fini M, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686-706.
61. Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports Med. 2005;35(9):779-830.
62. Mojtahedi MC, et al. Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev. 2008;45(6):851-61.
63. Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol. 2010;257(3):410-8.
64. De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 2008;99(1):23-43.
65. Dovio A, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89(10):4923-8.
66. Tuzun S, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9(6):600-4.
67. Schwid SR, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996;53(8):753-7.
68. Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia. 1999;40(6):745-7.
69. Ghezzi A, et al. Epilepsy in multiple sclerosis. Eur Neurol. 1990;30(4):218-23.
70. Petty SJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65(9):1358-65.
71. Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8(1):34-46.
72. Truini A, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260(2):351-67.
73. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.
74. Daniell HW. OPioid osteoporosis. Arch Internal Med. 2004;164(3):338.
75. Elhassan AM, et al. Methionine-enkephalin in bone and joint tissues. J Bone Miner Res. 1998;13(1):88-95.
76. Loskutova N, et al. Bone density and brain atrophy in early Alzheimer's disease. J Alzheimers Dis. 2009;18(4):777-85.
77. Batista S, et al. Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Mult Scler. 2012;18(10):1459-65.
78. Shuhaibar M, et al. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009;178(1):43-5.
79. Weinstock-Guttman B, et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006;12(5):541-50.
80. National Osteoporosis Foundation. NOF's clinicians' guide to the prevention and treatment of osteoporosis (http://nof.org/hcp/resources/913.
81. Ishii M, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458(7237):524-8.
82. Sato C, et al. Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun. 2012;423(1):200-5.
83. Huang C, et al. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. Cell Tissue Res. 2012;347(3):553-66.
84. Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-97.
85. Melton LJ 3rd, et al. Potential extensions of the US FRAX algorithm. J Osteoporos. 2012;2012:528790.
86. Dennison EM, et al. Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW). Bone. 2012;50(6):1288-93.
87. Bazelier MT, et al. A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology. 2012;79(9):922-8.
88. Sundstrom P, Salzer J. Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. Biomark Med. 2013;7(2):193-5.
89. Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci. 2009;286(1-2):104-8.
90. Weinstock-Guttman B, et al. Vitamin D and multiple sclerosis. Neurologist. 2012;18(4):179-83.
91. Ascherio A, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306-14.
92. Kmietowicz Z. NICE publishes osteoporosis guidance after more than six years of consultation. BMJ. 2008;337:a2397.
93. Compston J. NICE: its influence in treating osteoporosis in the UK and beyond. Ther Adv Musculoskelet Dis. 2009;1(2):63-6.
94. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20
95. Cummings SR, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686-96.
96. Trojano M, et al. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci. 2003;24(Suppl 5):S268-70.
97. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304-6.
98. Black DM, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761-71.
99. Odvina CV, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol. 2010;72(2):161-8.
100. Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014;29(1):1-23.
101. Formica CA, et al. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int. 1997;61(2):129-33.